Evidence map›Paper›PMID 41583590›Full record

ReviewStroke (Hoboken, N.J.)2024

Management of Incomplete Microcirculatory Reperfusion After Endovascular Thrombectomy: Focus on Inhibition of the Glycoprotein IIb/IIIa Receptor Pathway.

Neeharika Krothapalli, Thomas Ortel, Devin McBride, Adam de Havenon, Lauren H Sansing, David Hasan, Brian Mac Grory

Abstract readReview
In one paragraph

Review in Stroke (Hoboken, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Neeharika KrothapalliDepartment of Neurology University of Connecticut School of Medicine Farmington CT.
Thomas OrtelDepartment of Medicine Duke University School of Medicine Durham NC.
Devin McBrideDepartment of Neurosurgery McGovern Medical School University of Texas Health Science Center Houston TX.
Adam de HavenonDepartment of Neurology Center for Brain and Mind Health Yale University School of Medicine New Haven CT.
Lauren H SansingDepartment of Neurology Center for Brain and Mind Health Yale University School of Medicine New Haven CT.
David HasanDepartment of Neurosurgery Duke University School of Medicine Durham NC.
Brian Mac GroryDepartment of Neurology Duke University School of Medicine Durham NC.ORCID https://orcid.org/0000-0003-3914-8419

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endovascular thrombectomy (EVT) is one of the most effective therapies for acute ischemic stroke attributable to large-vessel occlusion but, despite successful treatment, there remains a significant number of patients with disability. The phenomenon of incomplete microcirculatory reperfusion or no reflow is thought to underlie a substantial proportion of cases with unfavorable outcome. This phenomenon likely arises from platelet aggregation and endothelial edema impacting the cerebral microvasculature, vessels that are below the resolution of digital subtraction angiography. Although incomplete microcirculatory reperfusion prevents tissue recovery and poses a significant clinical challenge, there are multiple therapeutic options administered early after recanalization that have been shown to be promising. In this review, we discuss incomplete microcirculatory reperfusion after EVT and highlight various treatment approaches with a particular focus on antiplatelet therapy, including inhibition of the glycoprotein IIb/IIIa receptor pathway. We also review the rigor of previous studies exploring the use of intravenous and intraarterial administration of tirofiban in neurologic disease before EVT, during EVT, after EVT, or as rescue therapy to determine its effect on clinical outcomes.

Identifiers

PMID41583590
PMCPMC12778492

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.